Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
Merck
Mallinckrodt
Boehringer Ingelheim

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for SGN-30

See Plans and Pricing

« Back to Dashboard

What is the drug development status for SGN-30?

SGN-30 is an investigational drug.

There have been 71 clinical trials for SGN-30. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.

The most common disease conditions in clinical trials are Lymphoma, Hodgkin Disease, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc., and Genentech, Inc.

There are six US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for SGN-30
TitleSponsorPhase
A Study of SGN-CD228A in Advanced Solid TumorsSeattle Genetics, Inc.Phase 1
A Safety Study of SGN-CD47M in Patients With Solid TumorsSeattle Genetics, Inc.Phase 1
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)TakedaPhase 1/Phase 2

See all SGN-30 clinical trials

Clinical Trial Summary for SGN-30

Top disease conditions for SGN-30
Top clinical trial sponsors for SGN-30

See all SGN-30 clinical trials

US Patents for SGN-30

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SGN-30   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
SGN-30   Start Trial Methods for glycoprotein remodeling using endoglycosidase mutants CHO Pharma Inc. (Taipei, TW) Academia Sinica (Taipei, TW)   Start Trial
SGN-30   Start Trial Compositions and methods for cancer immunotherapy Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP)   Start Trial
SGN-30   Start Trial Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD)   Start Trial
SGN-30   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SGN-30

Drugname Country Document Number Estimated Expiration Related US Patent
SGN-30 Australia 2013220749 2032-02-15   Start Trial
SGN-30 Brazil 112014019627 2032-02-15   Start Trial
SGN-30 Canada 2862476 2032-02-15   Start Trial
SGN-30 China 104114705 2032-02-15   Start Trial
SGN-30 China 108570468 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Boehringer Ingelheim
McKinsey
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.